Accordingly, the American College of Cardiology (ACC) and the American Heart Association (AHA) have issued guideline recommendations stating that PCSK9 inhibitors should be used in adults with FH who fail to meet the LDL-C target on maximally tolerated high-intensity statin therapy combined with ezetimibe [13]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.